Herein, azadipeptidomimetic molecules were designed and synthesized using a quinoline‐histidine‐amino acid sequence with terminal amino acid modification. In‐silico studies were carried out to evaluate the compound's HIV protease‐1 inhibition temperament. In‐vitro anti‐proliferative possessions of the test compounds were studied by executing a series of experiments, namely DNA binding, bovine serum albumin (BSA) binding capability, and cytotoxicity assay on MCF‐7 cells. The molecule 5j exhibited remarkable results in all experiments; it has an excellent DNA binding constant (3.76 × 105), higher serum albumin unbound concentration of 5.96%, and a significant antiproliferative effect on MCF‐7 cells with IC50 value 0.31 nM.